Analysis of NQO1 polymorphisms and p53 protein expression in patients with hepatocellular carcinoma

Histology and Histopathology

Volumn 24, Issue 10, 2009, Pages 1223-1232

  Chiu, Mei Miao ^a   Ko, Ying Ju ^a   Tsou, Ann Ping ^a   Chau, Gar Yang ^b   Chau, Yat Pang ^a  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

Hepatocellular carcinoma; NAD(P)H; P53 gene; Quinone oxidoreductase 1 (NQO1)

Indexed keywords

NQO1 PROTEIN, HUMAN; PROTEIN P53; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE);

AGED; ARTICLE; FEMALE; GENETIC POLYMORPHISM; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; LIVER TUMOR; MALE; MIDDLE AGED; TUMOR CELL LINE;

AGED; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER NEOPLASMS; MALE; MIDDLE AGED; NAD(P)H DEHYDROGENASE (QUINONE); POLYMORPHISM, GENETIC; TUMOR SUPPRESSOR PROTEIN P53;

EID: 78650707027     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Aleksunes L.M., Goedken M. and Manautou J.E. (2006). Up-regulation of NAD(P)H quinone oxidoreductase 1 during human liver injury. World J. Gastroenterol. 12, 1937-1940.
2. Asher G., Lotem J., Kama R., Sachs L. and Shaul Y. (2002a). NQO1 stabilizes p53 through a distinct pathway. Proc. Natl. Acad. Sci. USA 99, 3099-3104.
3. Asher G., Lotem J., Sachs L., Kahana C. and Shaul Y. (2002b). Mdm-2 and ubiquitin-independent p53 proteasomal degradation regulated by NQO1. Proc. Natl. Acad. Sci. USA 99, 13125-13130.
4. Bauer A.K., Faiola B., Abernethy D.J., Marchan R., Pluta L.J., Wong V.A., Roberts K., Jaiswal A.K., Gonzalez F.J., Butterworth B.E., Borghoff S., Parkinson H., Everitt J. and Recio L. (2003) Genetic susceptibility to benzene-induced toxicity: role of NADPH: quinone oxidoreductase-1. Cancer Res. 63, 929-935.
5. Begleiter A., Sivananthan K., Curphey T.J. and Bird R.P. (2003). Induction of NAD(P)H quinone: oxidoreductase1 inhibits carcinogeninduced aberrant crypt foci in colons of Sprague-Dawley rats. Cancer Epidemiol. Biomarkers Prev. 12, 566-572.
6. de Haan L.H., Pot G.K., Aarts J.M., Rietjens I.M. and Alink G.M. (2006). In vivo relevance of two critical levels for NAD(P)H:quinone oxidoreductase (NQO1)-mediated cellular protection against electrophile toxicity found in vitro. Toxicol. In Vitro 20, 594-600.
7. Danson S., Ward T.H., Butler J. and Ranson M. (2004). DT-diaphorase: a target for new anticancer drugs. Cancer Treat. 30, 437-449.
8. Giono L.E. and Manfredi J.J. (2006) The p53 tumor suppressor participates in multiple cell cycle checkpoints. J. Cell Physiol. 209, 13-20.
9. Gong X., Kole L., Iskander K. and Jaiswal A.K. (2007) NRH:quinone oxidoreductase 2 and NAD(P)H:quinone oxidoreductase 1 protect tumor suppressor p53 against 20s proteasomal degradation leading to stabilization and activation of p53. Cancer Res. 67, 5380-5388.
10. Harth V., Donat S., Ko Y., Abel J., Vetter H. and Bruning T. (2000) NAD(P)H quinone oxidoreductase 1 codon 609 polymorphism and its association to colorectal cancer. Arch. Toxicol. 73, 528-531.
11. Herath N.I., Leggett B.A. and MacDonald G.A. (2006) Review of genetic and epigenetic alterations in hepatocarcinogenesis. J. Gastroenterol. Hepatol. 21, 15-21.
12. Hupp T.R. (1999) Regulation of p53 protein function through alterations in protein-folding pathways. Cell Mol. Life Sci. 55, 88-95.
13. Ishikawa K., Funayama T., Ohde H., Inagaki Y. and Mashima Y. (2005). Genetic variants of TP53 and EPHX1 in Leber's hereditary optic neuropathy and their relationship to age at onset. Jpn. J. Ophthalmol. 49, 121-6.
14. Iskander K. and Jaiswal A.K. (2005). Quinone oxidoreductases in protection against myelogenous hyperplasia and benzene toxicity. Chem. Biol. Interact. 153-154, 147-157.
15. Joseph P., Xie T., Xu Y. and Jaiswal A.K. (1994). NAD(P)H:quinone oxidoreductase1 (DT-diaphorase): expression, regulation, and role in cancer. Oncol. Res. 6, 525-532.
16. Joseph P., Long D.J., Klein-Szanto A.J. and Jaiswal A.K. (2000). Role of NAD(P)H:quinone oxidoreductase 1 (DT diaphorase) in protection against quinone toxicity. Biochem. Pharmacol. 60, 207-214.
17. Kiyohara C., Yoshimasu K., Takayama K. and Nakanishi Y. (2005). NQO1, MPO, and the risk of lung cancer: a HuGE review. Genet. Med. 7, 463-478.
18. Liu Y., Zhu X., Zhu J., Liao S., Tang Q., Liu K., Guan X., Zhang J. and Feng Z. (2007). Identification of differential expression of genes in hepatocellular carcinoma by suppression subtractive hybridization combined cDNA microarray. Oncol. Reports 18, 943-951.
19. Long D.J 2nd., Waikel R.L., Wang X.J., Perlaky L., Roop D.R. and Jaiswal A.K. (2000). NAD(P)H:quinone oxidoreductase 1 deficiency increases susceptibility to benzo(a)pyrene-induced mouse skin carcinogenesis. Cancer Res. 60, 5913-5925.
20. Long D.J 2nd., Waikel R.L., Wang X.J., Roop D.R. and Jaiswal A.K. (2001). NAD(P)H:quinone oxidoreductase 1 deficiency and increased susceptibility to 7,12-dimethylbenz[a]-anthracene-induced carcinogenesis in mouse skin. J. Natl. Cancer Inst. 93, 1166-1170.
21. Long D.J. 2nd., Gaikwad A., Multani A., Pathak S., Montgomery C.A., Gonzalez F.J. and Jaiswal A.K. (2002). Disruption of the NAD(P)H:quinone oxidoreductase 1 (NQO1) gene in mice causes myelogenous hyperplasia. Cancer Res. 62, 3030-3036.
22. Lyn-Cook B.D., Yan-Sanders Y., Moore S., Taylor S., Word B. and Hammons G.J. (2006). Increased levels of NAD(P)H: quinone oxidoreductase 1 (NQO1) in pancreatic tissues from smokers and pancreatic adenocarcinomas: A potential biomarker of early damage in the pancreas. Cell Biol. Toxicol. 22, 73-80.
23. Malanga M. and Althaus F.R. (2005). The role of poly(ADP-ribose) in the DNA damage signaling network. Biochem. Cell Biol. 83, 354-364.
24. Miyasaka Y., Enomoto N. and Nagayama K. (2001). Analysis of differentially expressed genes in human hepatocellular carcinoma using suppression subtractive hybridization. Br. J. Cancer 85, 228-234.
25. Pang A., Ng I.O., Fan S.T. and Kwong Y.L. (2003). Clinicopathologic significance of genetic alterations in hepatocellular carcinoma. Cancer Genet. Cytogenet. 146, 8-15.
26. Qin L.X., Tang Z.Y., Ma Z.C., Wu Z.Q., Zhou X.D., Ye Q.H., Ji Y., Huang L.W., Jia H.L., Sun H.C. and Wang L. (2002). P53 immunohistochemical scoring: an independent prognostic marker for patients after hepatocellular carcinoma resection. World J. Gastroenterol. 8, 459-463.
27. Radjendirane V., Joseph P., Lee Y.H., Kimura S., Klein-Szanto A.J., Gonzalez F.J. and Jaiswal A.K. (1998). Disruption of the DT diaphorase (NQO1) gene in mice leads to increased menadione toxicity. J. Biol. Chem. 273, 7382-7389.
28. Rauth A.M., Goldberg Z. and Misra V. (1997). DT-diaphorase: possible roles in cancer chemotherapy and carcinogenesis. Oncol Res. 9, 339-349.
29. Saldivar S.J., Wang Y., Zhao H., Shao L., Lin J., Spitz M.R. and Wu X. (2005). An association between a NQO1 genetic polymorphism and risk of lung cancer. Mutat. Res. 582, 71-78.
30. Sarbia M., Bitzer M., Siegel D., Ross D., Schulz W.A., Zotz R.B., Kiel S., Geddert H., Kandemir Y., Walter A., Willers R. and Gabbert H.E. (2003). Association between NAD(P)H: quinone oxidoreductase 1 (NQ01) inactivating C609T polymorphism and adenocarcinoma of the upper gastrointestinal tract. Int. J. Cancer 107, 381-386.
31. Schlager J.J. and Powis G. (1990). Cytosolic NAD(P)H:(quinoneacceptor) oxidoreductase in human normal and tumor tissue: effects of cigarette smoking and alcohol. Int. J. Cancer 45, 403-409.
32. Sheen I.S., Jeng K.S. and Wu J.Y. (2003). Is p53 gene mutation an indicatior of the biological behaviors of recurrence of hepatocellular carcinoma? World J. Gastroenterol. 9, 1202-1207.
33. Siegel D. and Ross D. (2000). Immunodetection of NAD(P)H:quinone oxidoreductase 1 (NQO1) in human tissues. Free Radic. Biol. Med. 29, 246-253.
34. Siegel D., Anwar A., Winski S.L., Kepa J.K., Zolman K.L. and Ross D. (2001). Rapid polyubiquitination and proteasomal degradation of a mutant form of NAD(P)H:quinone oxidoreductase 1. Mol. Pharmacol. 59, 263-268.
35. Stewart Z.A. and Pietenpol J.A. (2001). p53 Signaling and cell cycle checkpoints. Chem. Res. Toxicol. 14, 243-263.
36. Strassburg A., Strassburg C.P., Manns M.P. and Tukey R.H. (2002). Differential gene expression of NAD(P)H: Quinone Oxidoreductase and NRH:Quinone Oxidoreductase in human hepatocellular and biliary tissue. Mol. Pharmacol. 61, 320-325.
37. Sunga N., Kohno T. and Yanagitani N. (2002). Contribution of the NQO1 and GSTT1 polymorphisms to lung adenocarcinoma susceptibility. Cancer Epidemiol. Biomarkers Prev. 11, 730-738.
38. Tanaka K., Kiyosawa N., Watanabe K. and Manabe S. (2007). Characterization of resistance to bromobenzene-induced hepatotoxicity by microarray. J. Toxicol. Sci. 32, 129-134.
39. Teufel A., Staib F., Kanzler S., Weinmann A., Schulze-Bergkamen H. and Galle P.R. (2007). Genetics of hepatocellular carcinoma. World J. Gastroenterol. 13, 2271-2282.
40. Tsvetkov P., Asher G., Reiss V., Shaul Y., Sachs L. and Lotem J. (2005). Inhibition of NAD(P)H:quinone oxidoreductase 1 activity and induction of p53 degradation by the natural phenolic compound curcumin. Proc. Natl. Acad. Sci. USA 102, 5535-5540.
41. Zhang J., Schulz W.A., Li Y., Wang R., Zotz R., Wen D., Siegel D., Ross D., Gabbert H.E. and Sarbia M. (2003). Association of NAD(P)H: quinone oxidoreductase 1 (NQO1) C609T polymorphism with esophageal squamous cell carcinoma in a German Caucasian and a northern Chinese population. Carcinogenesis 24, 905-909.